Nivalin (Galantamine Hydrobromide)

Galantamine works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine, and by positively modulating nicotinic acetylcholine receptors. This dual action increases the amount of acetylcholine available for neuronal signaling, addressing the cholinergic deficit seen in Alzheimer’s disease.

The appropriate dose of Nivalin is determined individually by a qualified prescriber based on the patient’s clinical condition, age, renal function, and tolerability. The prescribing physician will decide the starting dose and any necessary titration schedule.

Safety data for galantamine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To request Nivalin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both galantamine (Nivalin) and donepezil belong to the acetylcholinesterase inhibitor class, but galantamine also modulates nicotinic receptors, which may offer additional cognitive benefits for some patients. Choice of therapy depends on individual response, tolerability, drug‑interaction profile, and physician preference.

Nivalin tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Nivalin is taken orally, usually with water. It can be administered with or without food, although taking it with meals may reduce gastrointestinal upset. Patients should follow the dosing schedule prescribed by their healthcare provider and swallow tablets whole.

Serious adverse events include severe bradycardia, heart block, and hepatotoxicity manifested by elevated liver enzymes. Patients should be monitored for signs of cardiac conduction disturbances and liver dysfunction, especially during dose escalation or when taking interacting medications.

Nivalin is contraindicated in patients with known hypersensitivity to galantamine or any excipients, those with severe cardiac conduction disorders (e.g., sick‑sinus syndrome, second‑ or third‑degree AV block) without a pacemaker, and individuals with severe renal impairment unless dose adjustments are made.